American Society of Hematology

Fig. 6.

$Fig. 6. p36 MBPK activation is inhibited by the survival-promoting cytokine, IL-5, and enhanced by the Fas/CD95 agonist, CH-11. / Eosinophils were incubated in the absence and presence of either IL-5 (10 pM; A), or the Fas-activating antibody, CH-11 (100 ng/mL; B) for the indicated times. Cells were then lysed by the addition of ice-cold immunoprecipitaton buffer, and soluble fractions were prepared, separated by 10% SDS-PAGE, and the kinases detected by “in gel” renaturation assays using MBP as a substrate. Representative autoradiographs obtained from 3 independent experiments are shown.$

p36 MBPK activation is inhibited by the survival-promoting cytokine, IL-5, and enhanced by the Fas/CD95 agonist, CH-11.

Eosinophils were incubated in the absence and presence of either IL-5 (10 pM; A), or the Fas-activating antibody, CH-11 (100 ng/mL; B) for the indicated times. Cells were then lysed by the addition of ice-cold immunoprecipitaton buffer, and soluble fractions were prepared, separated by 10% SDS-PAGE, and the kinases detected by “in gel” renaturation assays using MBP as a substrate. Representative autoradiographs obtained from 3 independent experiments are shown.

This Feature Is Available To Subscribers Only